Review





Similar Products

96
Danaher Inc basolateral fluorescence
Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative <t>apical‐to‐basolateral</t> transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.
Basolateral Fluorescence, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microplate+reader/SpectraMax+iD3-ID5/pmc13643098-531-10-16
Average 96 stars, based on 1 article reviews
basolateral fluorescence - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

97
Danaher Inc spectramax m5 fluorescent spectrophotometric plate reader
Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative <t>apical‐to‐basolateral</t> transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.
Spectramax M5 Fluorescent Spectrophotometric Plate Reader, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microplate+reader/SpectraMax+M5+Series+Microplate+Readers/10__1038_slash_s41467___026___78140___5-326-2-2
Average 97 stars, based on 1 article reviews
spectramax m5 fluorescent spectrophotometric plate reader - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier

99
BMG Labtech fluostar omega fluorescence 566 microplate reader 167
Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative <t>apical‐to‐basolateral</t> transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.
Fluostar Omega Fluorescence 566 Microplate Reader 167, supplied by BMG Labtech, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microplate+reader/FLUOstar+Omega/10__1158_slash_2767___9764__crc___26___0150-83-5-12
Average 99 stars, based on 1 article reviews
fluostar omega fluorescence 566 microplate reader 167 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

98
Danaher Inc fluorescence intensity
Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative <t>apical‐to‐basolateral</t> transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.
Fluorescence Intensity, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microplate+reader/FlexStation+3/10__1016_slash_j__apsb__2026__09__024-120-7-23
Average 98 stars, based on 1 article reviews
fluorescence intensity - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier

99
BMG Labtech fluorescence microplate reader
Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative <t>apical‐to‐basolateral</t> transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.
Fluorescence Microplate Reader, supplied by BMG Labtech, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microplate+reader/FLUOstar+Omega/10__1038_slash_s41598___026___63336___y-123-13-18
Average 99 stars, based on 1 article reviews
fluorescence microplate reader - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

99
BMG Labtech clariostar fluorescent microplate reader
Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative <t>apical‐to‐basolateral</t> transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.
Clariostar Fluorescent Microplate Reader, supplied by BMG Labtech, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microplate+reader/CLARIOstar+Plus/10__1016_slash_j__mtadv__2026__100827-348-34-38
Average 99 stars, based on 1 article reviews
clariostar fluorescent microplate reader - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

86
Hangzhou Allsheng Instruments fluorescent microplate reader
Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative <t>apical‐to‐basolateral</t> transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.
Fluorescent Microplate Reader, supplied by Hangzhou Allsheng Instruments, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microplate+reader/microplate+reader/pm42142422-179-13-21
Average 86 stars, based on 1 article reviews
fluorescent microplate reader - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

99
BMG Labtech fluostar omega fluorescence 556 microplate reader
Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative <t>apical‐to‐basolateral</t> transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.
Fluostar Omega Fluorescence 556 Microplate Reader, supplied by BMG Labtech, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microplate+reader/FLUOstar+Omega/us12595312-723-5-11
Average 99 stars, based on 1 article reviews
fluostar omega fluorescence 556 microplate reader - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

96
Revvity multimode fluorescence microplate reader
Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative <t>apical‐to‐basolateral</t> transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.
Multimode Fluorescence Microplate Reader, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microplate+reader/VICTOR+Nivo+multimode+plate+reader/pm41931282-173-9-16
Average 96 stars, based on 1 article reviews
multimode fluorescence microplate reader - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative apical‐to‐basolateral transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.

Journal: Advanced Science

Article Title: 3D Bioprinted Blood–Brain–Tumor Barrier Spheroid‐Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS‐Producing Ruthenium as a Potential Therapeutic Candidate

doi: 10.1002/advs.78150

Figure Lengend Snippet: Cytotoxicity profiling and Transwell permeability assessment of test compounds across hCMEC/D3 and U‐87 MG cell models. (A1–A4) Cell viability of hCMEC/D3 human cerebral microvascular endothelial cells following 24 h treatment with Rh123 (A1), Ru (A2), Osi (A3), or TMZ (A4), assessed by CellTiter‐Glo luminescent cell viability assay. (B1–B3) Cell viability of U‐87 MG glioblastoma cells following 48 h treatment with Ru (B1), Osi (B2), or TMZ (B3), assessed by MTT assay. (C1–C4) Cumulative apical‐to‐basolateral transport profiles of Rh123 (C1), Ru (C2), Osi (C3), and TMZ (C4) across hCMEC/D3 monolayers in the presence (Ver+) or absence (Ver−) of the P‐glycoprotein inhibitor verapamil (Ver, 100 µM), measured at 15‐min intervals over 60 min. (D1–D4) Apparent permeability coefficients (P app ) of Rh123 (D1), Ru (D2), Osi (D3), and TMZ (D4) in the presence (Ver+) or absence (Ver−) of verapamil. ** p < 0.01, *** p < 0.001, **** p < 0.0001; n.s., not significant. Rh123, Rhodamine‐123; Ru, ruthenium compound; Osi, osimertinib; TMZ, temozolomide; Ver, verapamil. Data in (A1–A4) and (B1–B3) are presented as mean ± SD of n = 3 replicate wells per concentration seeded in parallel; data in (C1–C4) and (D1–D4) are presented as mean ± SD of n = 3 Transwell inserts seeded in parallel per condition. Statistical significance was assessed by ordinary one‐way ANOVA followed by Tukey's multiple‐comparisons test, using a two‐sided alpha of 0.05. Analyses were performed using GraphPad Prism 11.0.2.

Article Snippet: Following a 60‐min incubation at 37°C with agitation (100 rpm), basolateral fluorescence (Ex/Em 485/530 nm, iD3, Molecular Devices) was measured and compared with blank inserts to confirm barrier integrity.

Techniques: Profiling, Permeability, Cell Viability Assay, MTT Assay, Ruthenium, Concentration Assay